TaiMed Biologics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jimmy Chang

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.5yrs
CEO ownership0.2%
Management average tenureno data
Board average tenure4.5yrs

Recent management updates

Recent updates

TaiMed Biologics Inc.'s (GTSM:4147) Profit Outlook

Apr 20
TaiMed Biologics Inc.'s (GTSM:4147) Profit Outlook

TaiMed Biologics Inc. (GTSM:4147) Analysts Just Trimmed Their Revenue Forecasts By 18%

Mar 16
TaiMed Biologics Inc. (GTSM:4147) Analysts Just Trimmed Their Revenue Forecasts By 18%

TaiMed Biologics'(GTSM:4147) Share Price Is Down 67% Over The Past Five Years.

Feb 09
TaiMed Biologics'(GTSM:4147) Share Price Is Down 67% Over The Past Five Years.

Loss-Making TaiMed Biologics Inc. (GTSM:4147) Set To Breakeven

Jan 05
Loss-Making TaiMed Biologics Inc. (GTSM:4147) Set To Breakeven

TaiMed Biologics (GTSM:4147) Has Debt But No Earnings; Should You Worry?

Dec 01
TaiMed Biologics (GTSM:4147) Has Debt But No Earnings; Should You Worry?

CEO

Jimmy Chang

2.5yrs

Tenure

Mr. Chin-Ming Chang, also known as "Jimmy", Ph D., serves as Independent director of Genovate Biotechnology Co., Ltd. since May 29, 2023.He has been President and Chief Executive Officer of TaiMed Biologi...


Board Members

NamePositionTenureCompensationOwnership
Shiren S. Lee
Independent Director7.6yrsno datano data
Ta-mon Tseng
Director6.3yrsno datano data
Chi-Chuan Chen
Director11.5yrsno data0.12%
NT$ 28.3m
James N. Chang
Chairman & Spokesperson27.5yrsno datano data
Gwo-Fong Lin
Independent Director4.5yrsno datano data
Tien-Chieh Lee
Director3.8yrsno data0.0015%
NT$ 334.5k
Shih Chia Lin
Director2.6yrsno datano data
Hui-Chuan Chang
Director2.6yrsno datano data
Chin-Ting Chiu
Independent Director2.6yrsno datano data

4.5yrs

Average Tenure

65.5yo

Average Age

Experienced Board: 4147's board of directors are considered experienced (4.5 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 20:26
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TaiMed Biologics Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yenya KuoCapital Securities Corporation
Jianzheng WuCapital Securities Corporation
Chu WangCitigroup Inc